Reaction
Lip Ulceration reporting signals
As of the last recalculation, Lip Ulceration appears in 1,156 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 42.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 22 | 42.3 | 42.4 |
| Tofacitinib Citrate | 18 | 25.1 | 25.1 |
| Trimethoprim | 13 | 20.1 | 20.1 |
| Cefuroxime | 11 | 17.5 | 17.5 |
| Lapatinib | 13 | 15.2 | 15.3 |
| Escitalopram Oxalate | 49 | 12.6 | 12.6 |
| Fludarabine Phosphate | 26 | 12.2 | 12.2 |
| Vemurafenib | 8 | 12.1 | 12.1 |
| Busulfan | 9 | 10.4 | 10.4 |
| Voriconazole Injection | 12 | 10.0 | 10.0 |
| Golimumab | 42 | 9.1 | 9.1 |
| Bleomycin Sulfate | 5 | 8.7 | 8.8 |
| Loratadine And Pseudoephedrine Sulfate | 3 | 6.8 | 6.8 |
| Certolizumab Pegol | 42 | 6.7 | 6.7 |
| Crizotinib | 4 | 5.7 | 5.7 |